Pancreatic Cancer Long Survivals
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Physiology and Pathology".
Deadline for manuscript submissions: 31 January 2025 | Viewed by 1327
Special Issue Editors
Interests: pancreatic cancer; biomarker; neoadjuvant therapy; target therapy
Interests: pancreatic cancer; biomarker; neoadjuvant therapy; target therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most difficult tumors to treat. Radical surgery is the only potentially curative treatment; however, even in the group of radically resected patients, the five-year survival rate is below 25%. There are several reasons for the dismal prognosis of PDAC, particularly the late onset of symptoms, biological aggressiveness characterized by early metastasis and impressive resistance to many anticancer agents.
Unfortunately, progress in the management of both resectable and borderline-resectable PDAC, but especially of locally advanced/metastatic disease has been very modest in the last decades. In fact, chemotherapy regimens (gemcitabine and abraxane or FOLFIRINOX) are considered the gold standard in the treatment of locally advanced or metastatic PDAC, though providing only slight improvements in the overall survival, reaching few months at best. No target therapies or immunotherapy approaches are nowadays clearly effective for PDAC. Additionally, no predictive biomarkers of treatment effectiveness are used routinely in clinical practice. Only the implementation of genetic testing can change a very narrow treatment landscape for small subsets of patients with actionable aberrations. In particular, in BRCA1/2-mutated patients, olaparib (PARP inhibitor) may be proposed as a maintenance strategy. Nevertheless, the differences in outcomes of PDAC patients exist. Therefore, understanding the characteristics of long pancreatic cancer survivals may be clinically important.
Dr. Francesco Leonardi
Dr. Ingrid Garajova
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- long survival
- outcome
- pancreatic adenocarcinoma
- long-term survival
- surgical resection
- chemotherapy
- NGS
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
